DOCKET NO.: JANM-0773/PRD2061USPCT PATENT
Application No.: 10/560,300

Office Action Dated: June 9, 2009

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:



1. (Currently Amended) A compound of formula (I)

$$\begin{array}{c} CR^5 \\ CH_2 - N - C \\ R^1 - R^2 \end{array} \quad (1).$$

a stereochemically isomeric form thereof, an N-oxide form thereof, or a pharmaceutically acceptable acid or base addition salt thereof, wherein

-R1-R2- is a bivalent radical of formula

-O-CH ₂ -O-	(a-1),
-O-CH ₂ -CH ₂ -	(a-2),
-O-CH ₂ -CH ₂ -O-	(a-3),
-O-CH ₂ -CH ₂ -CH ₂ -	(a-4),
-O-CH ₂ -CH ₂ -CH ₂ -O-	(a-5),
-O-CH ₂ -CH ₂ -CH ₂ -CH ₂ -	(a-6),
-O-CH ₂ -CH ₂ -CH ₂ -CH ₂ -O	(a-7),
O CH2 CH2 CH2 CH2 CH2	—(a 8),

wherein in said bivalent radicals optionally one or two hydrogen atoms on the same or a different carbon atom may be replaced by $C_{1.6}$ alkyl or hydroxy,

- R3 is hydrogen, halo, C1-6alkyl or C1-6alkyloxy;
- R⁴ is hydrogen, halo, C₁₋₆alkyl; C₁₋₆alkyl substituted with cyano, or C₁₋₆alkyloxy; C₁₋₆alkyloxy; cyano; amino or mono or di(C₁₋₆alkyl)amino;
- R⁵ is hydrogen or C₁₋₆alkyl, and the -OR⁵ radical is situated at the 3- or 4-position of the piperidine moiety;
- L is a radical of formula

-Alk-R ⁶	(b-1),
-Alk-X-R ⁷	(b-2),
-Alk-Y-C(=O)-R ⁹	(b-3),
-Alk-C(=O)-NH-C(=O)-R ¹¹	(b-4),
-Alk-C(=O)-NH-SO ₂ -R ¹¹	(b-5),
-Alk-SO ₂ -NH-C(=O)-R ¹¹	(b-6),
-Alk-SO ₂ -NH-SO ₂ -R ¹¹	(b-7),

Page 2 of 11

DOCKET NO.: JANM-0773/PRD2061USPCT Application No.: 10/560,300 Office Action Dated: June 9, 2009

wherein each Alk is C1-12alkanediyl; and

R⁶ is aminosulfonyl optionally substituted with C_{1.4}alkyl, C_{3.6}cycloalkyl or phenyl;

R⁷ is C_{1.6}alkylsulfonyl;

X is NR⁸; said R⁸ being C_{1.6}alkyl;

R⁹ is C₁₋₆alkylsulfonylamino;

Y is a O, S, or NR10 wherein R10 is hydrogen or C1-6alkyl; and

R¹¹ is C₁₋₆alkyl or phonyl, wherein the -OR5 radical is situated at the 3-position.

- (Previously Presented) The compound as claimed in claim 1 wherein the -OR⁵-radient is situated at the 3-position of the piperidine moiety, having the trans configuration.
- (Previously Presented) The compound as claimed in claim 2 wherein the absolute configuration of said piperidine moiety is (3S, 4S).
- (Previously Presented) The compound as claimed in claim 1 wherein L is a radical of formula (b-1) wherein Alk is C₁₋₄alkanediyl, and R⁶ aminosulfonyl or aminosulfonyl substituted with C₁₋₄alkyl or phenyl.
- (Previously Presented) The compound as claimed in claim 1 wherein L is a radical (b-5) wherein Alk is C_{1.44}alkanediyl, and R¹¹ is C_{1.44}alkyl.
- (Previously Presented) The compound as claimed in claim 1 wherein L is a radical (b-7) wherein Alk is C₁₋₄alkanediyl, and R¹¹ is C₁₋₄alkyl.
- (Previously Presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically active amount of a compound according to claim
 1.
- 8. (Canceled)
- 9. (Canceled)
- No. (Original) A process for preparing a compound of formula (I) wherein
 - a) an intermediate of formula (II) is reacted with an carboxylic acid derivative of formula (III) or a reactive functional derivative thereof;



 b) an intermediate of formula (IV) is N-alkylated with an intermediate of formula (V), in a reaction-inert solvent and, optionally in the presence of a suitable base;

wherein in the above reaction schemes the radicals -R¹-R²-, R³, R⁴, R⁵, and L are as defined in claim 1 and W is an appropriate leaving group:

- c) or, compounds of formula (I) are converted into each other following art-known transformation reactions; or if desired; a compound of formula (I) is converted into a pharmaceutically acceptable acid addition salt, or conversely, an acid addition salt of a compound of formula (I) is converted into a free base form with alkali; and, if desired, preparing stereochemically isomeric forms thereof.
- 11. (Withdrawn) A method for the treatment of 5HT+related disorders comprising administering to a patient in need thereof an effective amount of a compound according to claim.

disorders

- 12. (Withdrawn) A method for treating patients suffering from gastrointestinal conditions of the patient an effective amount of a compound according to claim 1.
- 10

 |27. (Withdrawm) A method for treating hypermotility, irritable bowel syndrome, constipation or diarrhea predominant IBS, pain and non-pain predominant IBS and bowel Page 4 of 11



DOCKET NO.: JANM-0773/PRD2061USPCT Application No.: 10/560,300 Office Action Dated: June 9, 2009

hypersensitivity comprising administering to a patient in need thereof an effective amount of a compound according to claim 1.